PDNA-lipoplexes engrafted with flagellin-related peptide induce potent immunity and anti-tumour effects

Vaccine

Volumn 29, Issue 40, 2011, Pages 6911-6919

  Faham, Abdus ^a   Herringson, Thomas ^a   Parish, Chris ^b   Suhrbier, Andreas ^c   Khromykh, Alexander A ^d   Altin, Joseph G ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b Australian National University   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

DNA vaccine; Flagellin related peptide; Immunity; Targeted lipoplexes; TLR5

Indexed keywords

3 (NITRILOACETIC ACID); CANCER VACCINE; CHELATING AGENT; COMPLEMENTARY DNA; DITETRADECYLAMINE; DNA VACCINE; EPITOPE; FLAGELLIN; FLAGELLIN DERIVED TOLL LIKE RECEPTOR 5 AGONIST PEPTIDE; GAMMA INTERFERON; LIPOPLEX; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLASMID DNA; POLYHISTIDINE TAG; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA IMMUNIZATION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG POTENCY; EMBRYO; ENGRAFTMENT; FEMALE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIPOSOMAL DELIVERY; LIVER; LUNG; LYMPHOCYTE COUNT; MELANOMA; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE ACTIVATION; TARGET CELL DESTRUCTION; TUMOR IMMUNITY;

AMINES; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; FLAGELLIN; GENE THERAPY; GENETIC VECTORS; HEK293 CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LIPIDS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NITRILOTRIACETIC ACID; PEPTIDES; VACCINES, DNA;

EID: 80052341153     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.045     Document Type: Article

References (38)

1. Steer H.J., Lake R.A., Nowak A.K., Robinson B.W. Harnessing the immune response to treat cancer. Oncogene 2010, 29(December (48)):6301-6313.
2. Schreurs M.W., de Boer A.J., Figdor C.G., Adema G.J. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res 1998, 58(June (12)):2509-2514.
3. Corr M., Lee D.J., Carson D.A., Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 1996, 184(October (4)):1555-1560.
4. Karkada M., Weir G.M., Quinton T., Fuentes-Ortega A., Mansour M. A liposome-based platform VacciMax, and its modified water-free platform DepoVax enhance efficacy of in vivo nucleic acid delivery. Vaccine 2010, 28(August (38)):6176-6182.
5. Seow Y., Wood M.J. Biological gene delivery vehicles: beyond viral vectors. Mol Ther 2009, 17(May (5)):767-777.
6. Daniel R., Smith J.A. Integration site selection by retroviral vectors: molecular mechanism and clinical consequences. Hum Gene Ther 2008, 19(June (6)):557-568.
7. Hartman Z.C., Appledorn D.M., Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 2008, 132(March (1-2)):1-14.
8. Herringson T.P., Patlolla R.R., Altin J.G. Targeting of plasmid DNA-lipoplexes to cells with molecules anchored via a metal chelator lipid. J Gene Med 2009, 11(November (11)):1048-1063.
9. Meyer O., Kirpotin D., Hong K., Sternberg B., Park J.W., Woodle M.C., et al. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J Biol Chem 1998, 273(June (25)):15621-15627.
10. U'Ren L., Kedl R., Dow S. Vaccination with liposome-DNA complexes elicits enhanced antitumor immunity. Cancer Gene Ther 2006, 13(November (11)):1033-1044.
11. Hirsch-Lerner D., Zhang M., Eliyahu H., Ferrari M.E., Wheeler C.J., Barenholz Y. Effect of " helper lipid" on lipoplex electrostatics. Biochim Biophys Acta 2005, 1714(August (2)):71-84.
12. Li S., Huang L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther 1997, 4(September (9)):891-900.
13. Felzmann T., Buchberger M., Jechlinger M., Kircheis R., Wagner E., Gadner H. Xenogenization by tetanus toxoid loading into lymphoblastoid cell lines and primary human tumor cells mediated by polycations and liposomes. Cancer Lett 2000, 161(December (2)):241-250.
14. Nguyen L.T., Atobe K., Barichello J.M., Ishida T., Kiwada H. Complex formation with plasmid DNA increases the cytotoxicity of cationic liposomes. Biol Pharm Bull 2007, 30(April (4)):751-757.
15. Godbey W.T., Wu K.K., Mikos A.G. Poly(ethylenimine)-mediated gene delivery affects endothelial cell function and viability. Biomaterials 2001, 22(March (5)):471-480.
16. Filion M.C., Phillips N.C. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta 1997, 1329(October (2)):345-356.
17. Nicolazzi C., Mignet N., de la Figuera N., Cadet M., Ibad R.T., Seguin J., et al. Anionic polyethyleneglycol lipids added to cationic lipoplexes increase their plasmatic circulation time. J Control Release 2003, 88(March (3)):429-443.
18. Hafez I.M., Ansell S., Cullis P.R. Tunable pH-sensitive liposomes composed of mixtures of cationic and anionic lipids. Biophys J 2000, 79(September (3)):1438-1446.
19. Mignet N., Richard C., Seguin J., Largeau C., Bessodes M., Scherman D. Anionic pH-sensitive pegylated lipoplexes to deliver DNA to tumors. Int J Pharm 2008, 361(September (1-2)):194-201.
20. Patil S.D., Rhodes D.G., Burgess D.J. Biophysical characterization of anionic lipoplexes. Biochim Biophys Acta 2005, 1711(June (1)):1-11.
21. Faham A., Altin J.G. Antigen-containing liposomes engrafted with flagellin-related peptides are effective vaccines that can induce potent antitumor immunity and immunotherapeutic effect. J Immunol 2010, 185(August (3)):1744-1754.
22. Khromykh A.A. Replicon-based vectors of positive strand RNA viruses. Curr Opin Mol Ther 2000, 2(October (5)):555-569.
23. Altin J.G., Banwell M.G., Coghlan P.A., Easton C.J., Nairn M.R., Offermann D.A. Synthesis of NTA(3)-DTDA - a chelator-lipid that promotes stable binding of His-tagged proteins to membranes. Aust J Chem 2006, 59(5):302-306.
24. Anraku I., Harvey T.J., Linedale R., Gardner J., Harrich D., Suhrbier A., et al. Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity. J Virol 2002, 76(April (8)):3791-3799.
25. Faham A., Bennett D., Altin J.G. Liposomal Ag engrafted with peptides of sequence derived from HMGB1 induce potent Ag-specific and anti-tumour immunity. Vaccine 2009, 27(September (42)):5846-5854.
26. Simoes S., Slepushkin V., Duzgunes N., Pedroso de Lima M.C. On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes. Biochim Biophys Acta 2001, 1515(November (1)):23-37.
27. Drummond D.C., Zignani M., Leroux J. Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res 2000, 39(September (5)):409-460.
28. Sakurai F., Terada T., Yasuda K., Yamashita F., Takakura Y., Hashida M. The role of tissue macrophages in the induction of proinflammatory cytokine production following intravenous injection of lipoplexes. Gene Ther 2002, 9(August (16)):1120-1126.
29. Santel A., Aleku M., Keil O., Endruschat J., Esche V., Fisch G., et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 2006, 13(August (16)):1222-1234.
30. Herringson T.P., Altin J.G. Effective tumor targeting and enhanced anti-tumour effect of liposomes engrafted with peptides specific for tumour lymphatics and vasculature. Internat J Pharmaceut 2011, 411(June (1-2)):206-214.
31. Bekersky I., Fielding R.M., Dressler D.E., Kline S., Buell D.N., Walsh T.J. Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labelled AmBisome to healthy volunteers. J Clin Pharm 2001, 41(September (9)):963-971.
32. Awasthi V.D., Garcia D., Klipper R., Goins B.A., Phillips W.T. Neutral and anionic liposome-encapsulated hemoglobin: effect of postinserted poly(ethylene glycol)-distearoylphosphatidylethanolamine on distribution and circulation kinetics. J Pharmacol Exp Ther 2004, 309(April (1)):241-248.
33. Lewis J.D., Reilly B.D., Bright R.K. Tumor-associated antigens: from discovery to immunity. Int Rev Immunol 2003, 22(March-April (2)):81-112.
34. Le Moigne V., Robreau G., Mahana W. Homologous recombination with linear DNA to insert antigenic protein in the flagellin: improvement of the Th1 immune response. Microbiol Immunol 2006, 50(1):33-43.
35. Signori E., Iurescia S., Massi E., Fioretti D., Chiarella P., De Robertis M., et al. DNA vaccination strategies for anti-tumour effective gene therapy protocols. Cancer Immunol Immunother 2010, 59(October (10)):1583-1591.
36. Diebold S.S., Kursa M., Wagner E., Cotten M., Zenke M. Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells. J Biol Chem 1999, 274(July (27)):19087-19094.
37. Chamarthy S.P., Jia L., Kovacs J.R., Anderson K.R., Shen H., Firestine S.M., et al. Gene delivery to dendritic cells facilitated by a tumor necrosis factor alpha-competing peptide. Mol Immunol 2004, 41(July (8)):741-749.
38. Liu M. DNA Vaccines: an historical perspective and view to the future. Immunolog Rev 2011, 239:62-84.